Journals / BEYOGLU EYE JOURNAL / 2022 / Cilt: 7 - Sayı: 3

Comparison of Ranibizumab Treatment Response of Superior and Inferior Temporal Branch Retinal Vein Occlusion: A Year Follow-Up

Pages
207–212
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, more frequent injections were needed to achieve the same efficacy in superior temporal branch retinal vein occlusion.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of the study was to compare ranibizumab treatment response of macular edema secondary to superior and inferior temporal branch retinal vein occlusion.
📊
Key Findings & Data:Methods: Sixty-four eyes of 64 patients treated with 0.5 mg/0.05 mL ranibizumab due to macular edema secondary to branch retinal vein occlusion were enrolled in this retrospective study.
💡
Conclusion & Impact:However, more frequent injections were needed to achieve the same efficacy in superior temporal branch retinal vein occlusion.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of the study was to compare ranibizumab treatment response of macular edema secondary to superior and inferior temporal branch retinal vein occlusion. Methods: Sixty-four eyes of 64 patients treated with 0.5 mg/0.05 mL ranibizumab due to macular edema secondary to branch retinal vein occlusion were enrolled in this retrospective study. Thirty-eight eyes with superior temporal branch retinal vein occlusion were classified as Group 1 and 26 eyes with inferior temporal branch retinal vein occlusion as Group 2. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and the number of intravitreal injections were evaluated and compared between the groups. Results: The mean baseline, 3rd, 6th, 9th, and 12th month BCVA values in Group 1 were 0.77±0.47, 0.37±0.20, 0.37±0.22, 0.38±0.24, and 0.35±0.18 logarithm of the minimum angle of resolution (logMAR) and in Group 2 were 0.75±0.45, 0.37±0.18, 0.35±0.19, 0.32±0.17, and 0.28±0.20 logMAR, respectively. The mean baseline, 3rd, 6th, 9th, and 12th month CMT values in Group 1 were 522.92±136.01, 318.03±66.65, 287.53±48.27, 271.95±32.47, and 280.47±91.66 μm and in Group 2 were 524.08±145.51, 289.85±53.08, 268.96±31.57, 260.77±30.22, and 244.04±44.78 μm, respectively. BCVA and CMT improved significantly within both groups after the treatment (p0.05). However, a significantly higher number of injections was needed for Group 1. Conclusion: Ranibizumab improved the visual and anatomical outcomes similarly in both superior and inferior temporal branch retinal vein occlusion with macular edema. However, more frequent injections were needed to achieve the same efficacy in superior temporal branch retinal vein occlusion.

🔖

Cite This Article

KUMRAL, E. T., YENEREL, N. M., ERÇALIK, N. Y., KARABAŞ, L. (2022). Comparison of Ranibizumab Treatment Response of Superior and Inferior Temporal Branch Retinal Vein Occlusion: A Year Follow-Up. BEYOGLU EYE JOURNAL, Cilt: 7 - Sayı: 3, 207–212. https://ajindex.com/articles/649046

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Parodi MB, Bandello F. Branch retinal vein occlusion: Classification and treatment. Ophthalmologica 2009;223:298–305
  2. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: The beaver dam eye study. Arch Ophthalmol 2008;126:513–8
  3. Feist RM, Ticho BH, Shapiro MJ, Farber M. Branch retinal vein occlusion and quadrantic variation in arteriovenous crossings. Am J Ophthalmol 1992;113:664–8
  4. Wong TY, Scott IU. Clinical practice. Retinal vein occlusion. N Engl J Med 2010;363:2135–44
  5. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147–63
  6. Noma H, Minamoto A, Funatsu H, Sukamoto H, Nakano K, Yamashita H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graffes Arch Clin Exp Ophthalmol 2006;244:309–15
  7. Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B, Schmucker C. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: A systematic review. PLoS One 2013;8:e78538
  8. Bandello F, Augustin A, Tufail A, Leaback R. A 12-month, multicenter, parallel-group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol 2018;28:697–705
  9. Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-Month results of the brıghter study. Ophthalmology 2017;124:1778–87
  10. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Bravo investigators. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102–12
  11. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions: Long term follow-up in the HORIZON trial. Ophthalmology 2012;119:802–9
  12. Ozkaya A, Alkin Z, Yesilkaya C, Erdogan G, Perente I, Taskapili M. Ranibizumab in macular edema secondary to retinal vein occlusion in a real life practice: A retrospective case series. Beyoglu Eye J 2016;1:5–9
  13. Yuksel B, Karti O, Celik O, Kerci SG, Kusbeci T. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion. Clin Exp Optom 2018;101:116–22
  14. Chatziralli I, Theo